KENTEPOZIDIS NIKOLAOS

Education & Academic Titles

• Graduate of the Military School of Officers, Faculty of Medicine, Aristotle University of Thessaloniki
• Specialization in Internal Medicine-Hematology, 251 Hellenic Air-force General Hospital, “Evaggelismos” General Hospital, under the supervision of Professor Theofanis Oikonomopoulos
• Specialization in Medical Oncology, School of Medicine, University of Crete, under the supervision of Professor Vasileios Georgoulias
• Fellowship in Thoracic Oncology (Lung cancer- Mesothelioma), Christie Hospital NHS, Manchester, United Kingdom
• National and Kapodistrian University of Athens, School of Medicine, Post-graduate degree: “Human neoplastic diseases: clinical, pathological and anatomical approach and research”
• Doctorate awarded by the School of Medicine, University of Athens

Doctoral Thesis

Doctoral thesis, School of Medicine, National and Kapodistrian University of Athens

Professional Experience

• Chief of the Department of Oncology, 251 Hellenic Air-force General Hospital, since 2008
• Physician associate to "Metropolitan General" Private Hospital
• Associate to the 2nd Oncology Clinic, “Hygeia” Private Hospital, 1999-2002 (Chief: Mr. Paris Kosmidis)

Clinical Interest

• Lung cancer
• Breast cancer
• Gynecological cancer
• Gastrointestinal cancer
• Urological cancer

ΙΝΤERNATIONAL PUBLICATIONS

1. Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.
   Syrios J, Kouroussis C, Kotsakis A, Kentepozidis N, Kontopodis E, Kalbakis K, Vardakis N, Hatzidaki D, Polyzos A, Georgoulias V; GU Working Group of the Hellenic Oncology Research Group (HORG), Athens, Greece.
   Minerva Ginecol. 2019 Feb 6. doi: 10.23736/S0026-4784.19.04249-7. [Epub ahead of print]
   PMID: 30727721
2. Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG).
   Tsironis G, Koutsoukos K, Athanasakis K, Tsiara A, Tzannis K, Gerolympou M, Visvikis A, Oikonomopoulos G, Kollia A, Giannopoulou E, Dimitra M, Kostouros E, Papatsoris A, Dellis A, Stravodimos K, Varkarakis I, Samantas E, Aravantinos G, Kentepozidis N, Christodoulou C, Bozionelou V, Dimopoulos MA, Bamias A.
   Expert Rev Pharmacoecon Outcomes Res. 2018 Nov 10:1-11. doi: 10.1080/14737167.2019.1546121. [Epub ahead of print]
   PMID: 30417707
3. Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group.
   Kentepozidis N, Economopoulou P, Liontos M, Kotsakis A, Boukovinas I, Vardakis N, Kontopodis E, Prinarakis E, Skaltsi T, Souglakos J, Georgoulias V.
   Ann Gastroenterol. 2018 Nov-Dec;31(6):698-704. doi: 10.20524/aog.2018.0311. Epub 2018 Sep 14.
   PMID: 30386120 Free PMC Article
4. Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG).
   Asimakopoulou N, Souglakos J, Kentepozidis N, Karampeazis A, Kotsakis A, Ziras N, Makrantonakis P, Prinarakis E, Vamvakas L, Georgoulias V; Hellenic Oncology Research Group.
   J Geriatr Oncol. 2019 Jan;10(1):143-148. doi: 10.1016/j.jgo.2018.08.002. Epub 2018 Oct 23.
   PMID: 30366852
5. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer.
   Pentheroudakis G, Kotoula V, Koliou GA, Karavasilis V, Samantas E, Aravantinos G, Kalogeropoulou L, Souglakos I, Kentepozidis N, Koumakis G, Sgouros J, Zarkavelis G, Efstratiou I, Laschos K, Petraki C, Tikas I, Poulios C, Voutsina A, Goudopoulou A, Bafaloukos D, Vrettou E, Kalogera-Fountzila A, Pectasides D, Fountzilas G.
   Clin Colorectal Cancer. 2018 Dec;17(4):e631-e637. doi: 10.1016/j.clcc.2018.06.003. Epub 2018 Jun 15.
   PMID: 29980490
6. Small cell carcinoma of the stomach: A report of two cases and a review of the literature.
   Bakogeorgos M, Kalkanis D, Katsaounis P, Ramfidis V, Speliades C, Pierrakou E, Papadopoulos S, Pantazopoulos N, Georgoulias V, Kotsakis A, Kentepozidis N.
   Mol Clin Oncol. 2018 Jul;9(1):11-16. doi: 10.3892/mco.2018.1624. Epub 2018 May 10.
   PMID: 29896397 Free PMC Article
7. Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
   Katsaounis P, Kotsakis A, Kentepozidis N, Polyzos A, Bakogeorgos M, Koinis F, Vamvakas L, Vardakis N, Kalbakis K, Boukovinas I, Varthalitis II, Prinarakis E, Georgoulias V, Souglakos J.
   Ann Gastroenterol. 2018 Jan-Feb;31(1):65-70. doi: 10.20524/aog.2017.0215. Epub 2017 Nov 27.
   PMID: 29333068 Free PMC Article
8. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group.
   Saloustros E, Nikolaou M, Kalbakis K, Polyzos A, Christofillakis C, Kentepozidis N, Pistamaltzian N, Kourousis C, Vamvakas L, Georgoulias V, Mavroudis D..Clin Breast Cancer. 2018 Feb;18(1):88-94. doi: 10.1016/j.clbc.2017.10.013. Epub 2017 Oct 24.
   PMID: 29153775
9. Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group.
   Mavroudis D, Saloustros E, Boukovinas I, Papakotoulas P, Kakolyris S, Ziras N, Christophylakis C, Kentepozidis N, Fountzilas G, Rigas G, Varthalitis I, Kalbakis K, Agelaki S, Hatzidaki D, Georgoulias V.
   Br J Cancer. 2017 Jul 11;117(2):164-170. doi: 10.1038/bjc.2017.158. Epub 2017 Jun 22.
   PMID: 28641315 Free PMC Article
10. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Koinis F, Agelaki S, Karavassilis V, Kentepozidis N, Samantas E, Peroukidis S, Katsaounis P, Hartabilas E, Varthalitis II, Messaritakis I, Fountzilas G, Georgoulias V, Kotsakis A.
    Br J Cancer. 2017 Jun 27;117(1):8-14. doi: 10.1038/bjc.2017.137. Epub 2017 May 16.
    PMID: 28510571 Free PMC Article
11. Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
    Messaritakis I, Politaki E, Plataki M, Karavassilis V, Kentepozidis N, Koinis F, Samantas E, Georgoulias V, Kotsakis A.Lung Cancer. 2017 Feb;104:16-23. doi:10.1016/j.lungcan.2016.12.008. Epub 2016 Dec 14.
    PMID: 28212995
12. Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
    J Souglakos, I Boukovinas, S Kakolyris, S Xynogalos, N Ziras, A Athanasiadis, N Androulakis, A Christopoulou, M Vaslamatzis, A Ardavanis, C Emmanouilides, I Bompolaki, C Kourousis, P Makrantonakis, C Christofyllakis, E Athanasiadis, N Kentepozidis, A Karampeazis, U Katopodi, A Anagnosopoulos, G Papadopoulos, E Prinarakis, A Kalisperi, D Mavroudis, V Georgoulias
    A Oncol. 2019 Aug 1;30(8):1304-1310. doi: 10.1093/annonc/mdz193
13. Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer
    Ioannis Kotsantis, Panagiota Economopoulou, Amanda Psyrri, Eirini Maratou, Dimitrios Pectasides, Helen Gogas, Nikolaos Kentepozidis, Giannis Mountzios, George Dimitriadis, Stavroula Giannouli
    Anticancer Res. 2019 Aug;39(8):4185-4190. doi: 10.21873/anticanres.13578
14. MINOAS: A Single-arm Translational Phase II Trial of FOLFIRI Plus Aflibercept as First-line Therapy in Unresectable, Metastatic Colorectal Cancer
    Alexios Matikas, John Souglakos, Panagiotis Katsaounis, Athanasios Kotsakis, Panagiotis Kouroupakis, Nikolaos Pantazopoulos, Nikolaos Kentepozidis, Adamantia Nikolaidi, Ippokratis Messaritakis, Ioanna Tzovara, Dora Hatzidaki, Efthymis Prinarakis, Vassilis Georgoulias
    Target Oncol. 2019 Jun;14(3):285-293. doi: 10.1007/s11523-019-00647-3
15. Small cell carcinoma of the stomach: A report of two cases and a review of the literature
    Marios Bakogeorgos, Dimitrios Kalkanis, Panagiotis Katsaounis, Vassilios Ramfidis, Chariklia Speliades, Ekaterini Pierrakou, Savvas Papadopoulos, Nikolaos Pantazopoulos, Vassilis Georgoulias, Athanasios Kotsakis, Nikolaos Kentepozidis
    Mol Clin Oncol. 2018 Jul;9(1):11-16. doi: 10.3892/mco.2018.1624. Epub 2018 May 10
16. Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG)
    Georgiops Tsironis, Konstantinos Koutsoukos, Konstantinos Athanasakis, Anna Tsiara, Kimon Tzannis, Margarita Gerolympou, Anastasios Visvikis, Georgios Oikonomopoulos, Alexandra Kollia, Efstathia Giannopoulou, Marialena Dimitra, Efthymios Kostouros, Athanasios Papatsoris, Athanasios Dellis, Konstantinos Stravodimos, Ioannis Varkarakis, Epaminontas Samantas, Gerasimos Aravantinos, Nikolaos Kentepozidis, Christos Christodoulou, Vasiliki Bozionelou, Meletios Athanasios Dimopoulos, Aristotle Bamias
    Expert Rev Pharmacoecon Outcomes Res. 2019 Aug;19(4):491-501
17. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer
    George Pentheroudakis, Vassiliki Kotoula, Georgia-Angeliki Koliou, Vasilios Karavasilis, Epaminontas Samantas, Gerasimos Aravantinos, Lydia Kalogeropoulou, Ioannis Souglakos, Nikolaos Kentepozidis, Georgios Koumakis, Joseph Sgouros, Georgios Zarkavelis, Ioannis Efstratiou, Konstantinos Laschos, Constantina Petraki, Ioannis Tikas, Christos Poulios, Alexandra Voutsina, Athina Goudopoulou, Dimitrios Bafaloukos, Eleni Vrettou, Anna Kalogera-Fountzila, Dimitrios Pectasides, George Fountzilas
    Clin Colorectal Cancer. 2018 Dec;17(4):e631-e637
18. Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group
    Nikolaos Kentepozidis, Panagiota Economopoulou, Michael Liontos, Athanasios Kotsakis, Ioannis Boukovinas, Nikolaos Vardakis, Emmanouil Kontopodis, Efthimios Prinarakis, Teressa Skaltsi, John Souglakos, Vassilis Georgoulias
    Ann Gastroenterol. Nov-Dec 2018;31(6):698-704. doi: 10.20524/aog.2018.0311. Epub 2018 Sep 14
19. Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG)
    Natalia Asimakopoulou, John Souglakos, Nikolaos Kentepozidis, Athanasios Karampeazis, Athanasios Kotsakis, Nikolaos Ziras, Paris Makrantonakis, Efthimios Prinarakis, Lambros Vamvakas, Vassilis Georgoulias, Hellenic Oncology Research Group
    J Geriatr Oncol. 2019 Jan;10(1):143-148. doi: 10.1016/j.jgo.2018.08.002. Epub 2018 Oct 23
20. Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study
    John Syrios, Charalambos Kouroussis, Athanasios Kotsakis, Nikolaos Kentepozidis, Emmanouil Kontopodis, Kostas Kalbakis, Nikolaos Vardakis, Dora Hatzidaki, Aris Polyzos, Vassilis Georgoulias, GU Working Group of the Hellenic Oncology Research Group (HORG)
    Minerva Ginecol. 2019 Jun;71(3):182-190. doi: 10.23736/S0026-4784.19.04249-7. Epub 2019 Feb 6
21. Frequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study
    Stavros K Kakkos, Eleni Arnaoutoglou, Ioannis A Tsolakis, Athanasios Giannoukas, Christos A Papadimitriou, Nikolaos Kentepozidis, Ioannis Boukovinas, Haralabos P Kalofonos, Nicos Labropoulos, Miltiadis Matsagkas
    Int Angiol. 2020 Apr;39(2):112-117. doi: 10.23736/S0392-9590.20.04272-8. Epub 2020 Feb 13
22. Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group
    Panagiotis Katsaounis, Athanasios Kotsakis, Nikolaos Kentepozidis, Aris Polyzos, Marios Bakogeorgos, Filippos Koinis, Lambros Vamvakas, Nikolaos Vardakis, Kostas Kalbakis, Ioannis Boukovinas, Ioannis I Varthalitis, Efthimios Prinarakis, Vassilis Georgoulias, John Souglakos
    Ann Gastroenterol. Jan-Feb 2018;31(1):65-70. doi: 10.20524/aog.2017.0215. Epub 2017 Nov 27
23. Weekly Paclitaxel and Carboplatin Plus Bevacizumab as First-Line Treatment of Metastatic Triple-Negative Breast Cancer. A Multicenter Phase II Trial by the Hellenic Oncology Research Group
    Emmanouil Saloustros, Michail Nikolaou, Konstantinos Kalbakis, Aris Polyzos, Charalampos Christofillakis, Nikolaos Kentepozidis, Nikolaos Pistamaltzian, Charalampos Kourousis, Lampros Vamvakas, Vasilios Georgoulias, Dimitris Mavroudis
    Clin Breast Cancer. 2018 Feb;18(1):88-94. doi: 10.1016/j.clbc.2017.10.013. Epub 2017 Oct 24
24. Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial
    Cesare Gridelli, Tudor Ciuleanu, Manuel Domine, Aleksandra Szczesna, Isabel Bover, Manuel Cobo, Nikolaos Kentepozidis, Konstantinos Zarogoulidis, Charalabos Kalofonos, Andrzej Kazarnowisz, Magdalena Korozan, Ramon de Las Penas, Margarita Majem, Antonio Chella, Frank Griesinger, Evangelos Bournakis, Parvis Sadjadian, Athanasios Kotsakis, Thierry Chinet, Kostantinos N Syrigos, Pierpaolo Correale, Catherine Gallou, Jeanne- Menez Jamet, Eleni- Kyriaki Vetsika, Kostas Kosmatopoulos, Vassilis Georgoulias, Vx-001-201 trial team
    Br J Cancer. 2020 May;122(10):1461-1466. doi: 10.1038/s41416-020-0785-y. Epub 2020 Mar 25
25. Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial
    Angelos Koutras, Flora Zagouri, Georgia-Angeliki Koliou, Elizabeth Psoma, Ioannis Chryssogonidis, Georgios Lazaridis, Dimitrios Tryfonopoulos, Athanasios Kotsakis, Eleni Res, Nikolaos K Kentepozidis, Evangelia Razis, Amanda Psyrri, Georgios Koumakis, Haralabos P Kalofonos, Meletios A Dimopoulos, George Fountzilas
    Br J Cancer. 2020 Aug;123(3):355-361. doi: 10.1038/s41416-020-0909-4. Epub 2020 Jun 3
26. Corrigendum to Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG): Annals of Oncology, Volume 26, Issue 7, July 2015, Pages 1333-1340
    D Mavroudis, E Saloustros, N Malamos, S Kakolyris, I Boukovinas, P Papakotoulas, N Kentepozidis, N Ziras, V Georgoulias, Breast Cancer Investigators of the Hellenic Oncology Research Group (HORG), Athens, Greece
    Ann Oncol. 2020 Mar;31(3):444-445. doi: 10.1016/j.annonc.2020.01.004. Epub 2020 Jan 31

Membership in Societies and Editorial Boards

• Member of HESMO (Hellenic Society of Medical Oncologists)
• Member of ASCO (American Society for Clinical Oncology)
• Member of ESMO (European Society for Medical Oncology)
• Member of HORG (Hellenic Oncology Research Group)

Research

International and Greek clinical trials on lung, breast, urinary tract, prostate, large intestine, kidney cancers

Contact

Telephone: +30 210 650 2143